AMBIsome Therapy Induction OptimisatioN (AMBITION): High Dose AmBisome for Cryptococcal Meningitis Induction Therapy in sub-Saharan Africa: Study Protocol for a Phase 3 Randomised Controlled Non-Inferiority Trial
DiscussionA safe, sustainable and easy to administer regimen of L-AmB that is non-inferior to seven days of daily amphotericin B deoxycholate therapy may reduce the number of adverse events seen in patients treated with amphotericin B deoxycholate and shorten hospital admissions, providing a highly favourable and implementable alternative to the current WHO recommended first-line treatment.Trial registrationISRCTN,ISRCTN72509687. Registered on 13 July 2017.
Source: Trials - Category: Research Source Type: clinical trials
More News: Abelcet | African Health | Botswana Health | Disability | Fluconazole | Hospitals | International Medicine & Public Health | Malawi Health | Men | Meningitis | Research | South Africa Health | Study | Toxicology | Uganda Health | WHO | Zimbabwe Health